Prodipine

Last updated

Prodipine
Prodipine.svg
Clinical data
Other namesBY-101; 1-Isopropyl-4,4-diphenylpiperidine
Routes of
administration 		Oral, intravenous injection [1]
Drug class Antiparkinsonian agents
Identifiers
  • 4,4-diphenyl-1-propan-2-ylpiperidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H25N
Molar mass 279.427 g·mol−1
3D model (JSmol)
  • CC(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
  • InChI=1S/C20H25N/c1-17(2)21-15-13-20(14-16-21,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17H,13-16H2,1-2H3
  • Key:CFOOTBBXHJHHMT-UHFFFAOYSA-N

Prodipine (INN Tooltip International Nonproprietary Name; developmental code name BY-101) is an experimental antiparkinsonian agent of the 4,4-diphenylpiperidine series related to budipine which was never marketed. [2] [3] [1] It was the predecessor of budipine and was similarly found to be effective in the treatment of Parkinson's disease. [1] However, prodipine produced side effects including gastrointestinal adverse effects, nausea and vomiting, and hypotension. [1] Due to the nausea and vomiting with the oral form, it could only be tolerated with intravenous administration. [1] As a result, budipine, which had fewer side effects, was developed instead. [1]

Contents

Pharmacology

The mechanism of action of these drugs is unknown. [1] [4] However, budipine is known to stimulate the catecholaminergic system and to increase motor activity and vigilance in animals. [1] It also increases brain dopamine, norepinephrine, and serotonin levels in animals treated with the monoamine depleting agent reserpine. [1] It does not affect monoamine oxidase nor does it appear to interact with dopamine D2 receptors. [1] Both budipine and prodipine have been described as "central stimulants" in addition to antiparkinsonian agents. [5] Prodipine is said to have more tendency to induce hyperactivity than budipine. [1]

Analogues

Besides prodipine and budipine, another close analogue, medipine, was also developed. [6] [7]

Related Research Articles

<span class="mw-page-title-main">Phenelzine</span> Antidepressant

Phenelzine, sold under the brand name Nardil, among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine family which is primarily used as an antidepressant and anxiolytic to treat depression and anxiety. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.

<span class="mw-page-title-main">MPTP</span> Chemical compound

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is an organic compound. It is classified as a tetrahydropyridine. It is of interest as a precursor to the monoaminergic neurotoxin MPP+, which causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons in the substantia nigra of the brain. It has been used to study disease models in various animals.

<span class="mw-page-title-main">Domperidone</span> Peripheral D2 receptor antagonist

Domperidone, sold under the brand name Motilium among others, is a dopamine antagonist medication which is used to treat nausea and vomiting and certain gastrointestinal problems like gastroparesis. It raises the level of prolactin in the human body and is used off label to induce and promote breast milk production. It may be taken by mouth or rectally.

<span class="mw-page-title-main">Selegiline</span> Monoamine oxidase inhibitor

Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Zelapar, and Emsam among others, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. It has also been studied and used off-label for a variety of other indications, but has not been formally approved for any other use. The medication, in the form licensed for depression, has modest effectiveness for this condition that is similar to that of other antidepressants. Selegiline is provided as a swallowed tablet or capsule or an orally disintegrating tablet (ODT) for Parkinson's disease and as a patch applied to skin for depression.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine", a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain.

<span class="mw-page-title-main">Nomifensine</span> Group of stereoisomers

Nomifensine, sold under the brand names Merital and Alival, is a norepinephrine–dopamine reuptake inhibitor (NDRI), i.e. a drug that increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters. This is a mechanism of action shared by some recreational drugs like cocaine and the medication tametraline (see DRI). Research showed that the (S)-isomer is responsible for activity.

<span class="mw-page-title-main">Tolcapone</span> Chemical compound

Tolcapone, sold under the brand name Tasmar, is a medication used to treat Parkinson's disease (PD). It is a selective, potent and reversible nitrocatechol-type inhibitor of the enzyme catechol-O-methyltransferase (COMT). It has demonstrated significant liver toxicity, which has led to suspension of marketing authorisations in a number of countries.

<span class="mw-page-title-main">Lisuride</span> Chemical compound

Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline class which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels. It is taken by mouth.

<span class="mw-page-title-main">Trace amine</span> Amine receptors in the mammalian brain

Trace amines are an endogenous group of trace amine-associated receptor 1 (TAAR1) agonists – and hence, monoaminergic neuromodulators – that are structurally and metabolically related to classical monoamine neurotransmitters. Compared to the classical monoamines, they are present in trace concentrations. They are distributed heterogeneously throughout the mammalian brain and peripheral nervous tissues and exhibit high rates of metabolism. Although they can be synthesized within parent monoamine neurotransmitter systems, there is evidence that suggests that some of them may comprise their own independent neurotransmitter systems.

<span class="mw-page-title-main">Piribedil</span> Drug used in the management of Parkinsons disease

Piribedil (trade names Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium and others) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.

<span class="mw-page-title-main">Dihydroergocryptine</span> Chemical compound

Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. It is taken by mouth.

<span class="mw-page-title-main">Pargyline</span> Chemical compound

Pargyline, sold under the brand name Eutonyl among others, is a monoamine oxidase inhibitor (MAOI) medication which has been used to treat hypertension but is no longer marketed. It has also been studied as an antidepressant, but was never licensed for use in the treatment of depression. The drug is taken by mouth.

<span class="mw-page-title-main">Budipine</span> Pharmaceutical drug

Budipine is an antiparkinson agent marketed for the treatment of Parkinson's disease.

<span class="mw-page-title-main">Levodopa</span> Dopaminergic medication

Levodopa, also known as L-DOPA and sold under many brand names, is a dopaminergic medication which is used in the treatment of Parkinson's disease and certain other conditions like dopamine-responsive dystonia and restless legs syndrome. The drug is usually used and formulated in combination with a peripherally selective aromatic L-amino acid decarboxylase (AAAD) inhibitor like carbidopa or benserazide. Levodopa is taken by mouth, by inhalation, through an intestinal tube, or by administration into fat.

<span class="mw-page-title-main">Levoamphetamine</span> CNS stimulant and isomer of amphetamine

Levoamphetamine is a stimulant medication which is used in the treatment of certain medical conditions. It was previously marketed by itself under the brand name Cydril, but is now available only in combination with dextroamphetamine in varying ratios under brand names like Adderall and Evekeo. The drug is known to increase wakefulness and concentration in association with decreased appetite and fatigue. Pharmaceuticals that contain levoamphetamine are currently indicated and prescribed for the treatment of attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy in some countries. Levoamphetamine is taken by mouth.

<span class="mw-page-title-main">Monoamine releasing agent</span> Class of compounds

A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of a monoamine neurotransmitter from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitter. Many drugs induce their effects in the body and/or brain via the release of monoamine neurotransmitters, e.g., trace amines, many substituted amphetamines, and related compounds.

<span class="mw-page-title-main">Emoxypine</span> Chemical compound

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties, but these purported properties of emoxypine have not been proven. Its chemical structure resembles that of pyridoxine (a type of vitamin B6).

Peripherally selective drugs have their primary mechanism of action outside of the central nervous system (CNS), usually because they are excluded from the CNS by the blood–brain barrier. By being excluded from the CNS, drugs may act on the rest of the body without producing side-effects related to their effects on the brain or spinal cord. For example, most opioids cause sedation when given at a sufficiently high dose, but peripherally selective opioids can act on the rest of the body without entering the brain and are less likely to cause sedation. These peripherally selective opioids can be used as antidiarrheals, for instance loperamide (Imodium).

<span class="mw-page-title-main">Monoamine neurotoxin</span> Compounds that damage or destroy monoaminergic neurons

A monoamine neurotoxin, or monoaminergic neurotoxin, is a drug that selectively damages or destroys monoaminergic neurons. Monoaminergic neurons are neurons that signal via stimulation by monoamine neurotransmitters including serotonin, dopamine, and norepinephrine.

<span class="mw-page-title-main">Mesdopetam</span> Chemical compound

Mesdopetam (INNTooltip International Nonproprietary Name; developmental code names IRL-790, IPN60170) is a dopamine D2 and D3 receptor antagonist with preference for the D3 receptor which is under development for the treatment of Parkinson's disease, drug-induced dyskinesia, and psychotic disorders. It has been described by its developers as having "psychomotor stabilizing" properties.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 Przuntek H, Stasch JP (1985). "Biochemical and Pharmacologic Aspects of the Mechanism of Action of Budipine". Clinical Experiences with Budipine in Parkinson Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 107–112. doi:10.1007/978-3-642-95455-9_15. ISBN   978-3-540-13764-1. Anticholinergics are widely used in addition to target drugs. A preliminary clinical trial (between 1974 and 1976) with prodipine in 161 patients with Parkinson's disease showed excellent to moderate improvement of resting tremor in 60 of the patients, while medication had to be discontinued in 98 patients owing to gastrointestinal side effects and hypotension. [...] Improvement of disability scores [with budipine] (Birkmayer and Neumayer 1972) gave evidence of a dopaminergic action although in some patients side effects were more frequent than with prodipine. [...] Budipine has less tendency to induce hyperactivity than its structural analogue prodipine and so with budipine anxious agitation states are a less frequent side effect. [...] Prodipin (1-isopropyl-4,4-diphenylpiperidine hydrochloride), the precursor of budipine, had already been found superior (unpublished study, Elena Klinik, Kassel, 1977) in this respect in a large number of patients. But the drug had one big disadvantage, it was tolerated on i.v. injection only. Oral doses caused nausea and vomiting and were thus not feasible. We now have high hopes for the product which was further developed, budipine.
  2. ↑ Gerstenbrand F, Poewe W, Stern G (1985). Clinical Experiences with Budipine in Parkinson Therapy. Springer Berlin Heidelberg. pp. 80, 107, 142. ISBN   978-3-642-95455-9 . Retrieved 28 September 2024.
  3. ↑ Vidaluc JL (1996). "MPTP as a Molecular Paradigm for Neurodegeneration. A Review of its Connections with Relevant Molecules". Current Medicinal Chemistry. Bentham Science Publishers. pp. 117–138. Retrieved 28 September 2024. Protective effect in the parkinsonian model with MPTP were displayed by prodipine (R=i-Pr) and budipine (R=t-Bu) in the 4,4-diphenylpiperidine series [110].
  4. ↑ Eltze M (1999). "Multiple mechanisms of action: the pharmacological profile of budipine". Journal of Neural Transmission. Supplementum. Journal of Neural Transmission. Supplementa. 56: 83–105. doi:10.1007/978-3-7091-6360-3_4. ISBN   978-3-211-83275-2. PMID   10370904.
  5. ↑ "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Geneva: World Health Organization. 2018. WHO/EMP/RHT/TSN/2018.1.
  6. ↑ Russ H, Pindur U, Przuntek H (1986). "The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site". Journal of Neural Transmission. 65 (3–4): 157–166. doi:10.1007/BF01249078. PMID   3011983. Other representatives of this class of substances, the 1-alkyl-4,4-diphenylpiperidines, such as, e.g., the 1-isopropyl analogue (prodipine) or the 1-methyl analogue (medipine) have similar pharmacological properties including marked tremorin and reserpin antagonism (Schaefer et al., 1984). The mechanism of action of the 1-alkyl-4,4- diphenylpiperidines is not yet understood in detail.
  7. ↑ Fonne-Pfister R, Meyer UA (October 1988). "Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism". Biochemical Pharmacology. 37 (20): 3829–3835. doi:10.1016/0006-2952(88)90063-9. PMID   2903741. Budipine (1-t-butyl-4,4-diphenylpiperidine) (Parkinson's disease treatment); Prodipine (1-isopropyl-4,4-diphenylpiperidine); Medipine (1-methyl-4,4-diphenylpiperidine)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.